

# Tatsuhiko Tachibana

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1599909/publications.pdf>

Version: 2024-02-01

35  
papers

2,735  
citations

430874

18  
h-index

377865

34  
g-index

37  
all docs

37  
docs citations

37  
times ranked

2443  
citing authors

#	ARTICLE	IF	CITATIONS
1	Epidermal Cell Differentiation in Arabidopsis Determined by a Myb Homolog, CPC. <i>Science</i> , 1997, 277, 1113-1116.	12.6	535
2	A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. <i>Nature Medicine</i> , 2012, 18, 1570-1574.	30.7	407
3	Role of a positive regulator of root hair development, CAPRICE, in Arabidopsis root epidermal cell differentiation. <i>Development (Cambridge)</i> , 2002, 129, 5409-5419.	2.5	303
4	Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. <i>Nature Biotechnology</i> , 2010, 28, 1203-1207.	17.5	286
5	Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor Activity. <i>PLoS ONE</i> , 2013, 8, e57479.	2.5	246
6	Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1348-1357.	3.4	141
7	Regulation of CAPRICE Transcription by MYB Proteins for Root Epidermis Differentiation in Arabidopsis. <i>Plant and Cell Physiology</i> , 2005, 46, 817-826.	3.1	109
8	Model Analysis of the Concentration-Dependent Permeability of P-gp Substrates. <i>Pharmaceutical Research</i> , 2010, 27, 442-446.	3.5	85
9	Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases. <i>Scientific Reports</i> , 2017, 7, 1080.	3.3	79
10	Engineered Monoclonal Antibody with Novel Antigen-Sweeping Activity In Vivo. <i>PLoS ONE</i> , 2013, 8, e63236.	2.5	75
11	Correction of Permeability with Pore Radius of Tight Junctions in Caco-2 Monolayers Improves the Prediction of the Dose Fraction of Hydrophilic Drugs Absorbed by Humans. <i>Pharmaceutical Research</i> , 2004, 21, 749-755.	3.5	72
12	Predicting Drug-Drug Interactions Involving the Inhibition of Intestinal CYP3A4 and P-Glycoprotein. <i>Current Drug Metabolism</i> , 2010, 11, 762-777.	1.2	57
13	Antibody to CD137 Activated by Extracellular Adenosine Triphosphate Is Tumor Selective and Broadly Effective In Vivo without Systemic Immune Activation. <i>Cancer Discovery</i> , 2021, 11, 158-175.	9.4	57
14	Prediction of Nonlinear Intestinal Absorption of CYP3A4 and P-Glycoprotein Substrates from their In Vitro Km Values. <i>Pharmaceutical Research</i> , 2012, 29, 651-668.	3.5	47
15	Antibody engineering to generate SKY59, a long-acting anti-C5 recycling antibody. <i>PLoS ONE</i> , 2018, 13, e0209509.	2.5	38
16	Inhibitory Fc $\gamma$ RIIb-Mediated Soluble Antigen Clearance from Plasma by a pH-Dependent Antigen-Binding Antibody and Its Enhancement by Fc Engineering. <i>Journal of Immunology</i> , 2015, 195, 3198-3205.	0.8	28
17	Evaluation of Methods for Predicting Drug-drug Interactions by Monte Carlo Simulation. <i>Drug Metabolism and Pharmacokinetics</i> , 2003, 18, 121-127.	2.2	22
18	Application of human FcRn transgenic mice as a pharmacokinetic screening tool of monoclonal antibody. <i>Xenobiotica</i> , 2014, 44, 1127-1134.	1.1	22

#	ARTICLE	IF	CITATIONS
19	Improvement of pharmacokinetic properties of therapeutic antibodies by antibody engineering. <i>Drug Metabolism and Pharmacokinetics</i> , 2019, 34, 25-41.	2.2	21
20	Quantitative prediction of therapeutic antibody pharmacokinetics after intravenous and subcutaneous injection in human. <i>Drug Metabolism and Pharmacokinetics</i> , 2017, 32, 208-217.	2.2	20
21	Identification of human IgG1 variant with enhanced FcRn binding and without increased binding to rheumatoid factor autoantibody. <i>MAbs</i> , 2017, 9, 844-853.	5.2	18
22	New method for the simultaneous estimation of intrinsic hepatic clearance and protein binding by matrix inhibition. <i>Biopharmaceutics and Drug Disposition</i> , 2008, 29, 7-16.	1.9	10
23	The importance of characterization of FITC-labeled antibodies used in tissue cross-reactivity studies. <i>Acta Histochemica</i> , 2011, 113, 472-476.	1.8	10
24	PK/PD analysis of a novel pH-dependent antigen-binding antibody using a dynamic antibody-antigen binding model. <i>Drug Metabolism and Pharmacokinetics</i> , 2016, 31, 123-132.	2.2	9
25	Quantitative prediction of P-glycoprotein-mediated drug-drug interactions and intestinal absorption using humanized mice. <i>British Journal of Pharmacology</i> , 2021, 178, 4335-4351.	5.4	7
26	Recent Advances in Translational Pharmacokinetics and Pharmacodynamics Prediction of Therapeutic Antibodies Using Modeling and Simulation. <i>Pharmaceutics</i> , 2022, 15, 508.	3.8	7
27	Simple Approach to Accurately Predict Pharmacokinetics of Therapeutic Monoclonal Antibodies after Subcutaneous Injection in Humans. <i>Clinical Pharmacokinetics</i> , 2021, 60, 111-120.	3.5	6
28	Predicting pharmacokinetic profile of therapeutic antibodies after iv injection from only the data after sc injection in cynomolgus monkey. <i>Xenobiotica</i> , 2017, 47, 194-201.	1.1	5
29	Estimation of Clearance and Bioavailability of Therapeutic Monoclonal Antibodies from Only Subcutaneous Injection Data in Humans Based on Comprehensive Analysis of Clinical Data. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1325-1334.	3.5	4
30	A Novel Total Drug Assay for Quantification of Anti-C5 Therapeutic Monoclonal Antibody in the Presence of Abundant Target. <i>AAPS Journal</i> , 2021, 23, 21.	4.4	2
31	Extrapolation of In Vitro Metabolic and P-Glycoprotein-Mediated Transport Data to In Vivo by Modeling and Simulations. , 2010, , 299-315.		2
32	Elimination of plasma soluble antigen in cynomolgus monkeys by combining pH-dependent antigen binding and novel Fc engineering. <i>MAbs</i> , 2022, 14, 2068213.	5.2	2
33	Regulatory systems of root patterning. <i>Journal of Plant Research</i> , 1998, 111, 315-321.	2.4	1
34	Antibody-based therapeutics. <i>Drug Metabolism and Pharmacokinetics</i> , 2019, 34, 1-2.	2.2	1
35	Analysis of Non-linear Pharmacokinetics of P-Glycoprotein Substrates in a Microfluidic Device Using a Mathematical Model that Includes an Unstirred Water Layer (UWL) Compartment. <i>Pharmaceutical Research</i> , 2021, 38, 1031-1039.	3.5	0